Literature DB >> 15044368

Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells.

V M Pushkarev1, D V Starenki, V A Saenko, H Namba, J Kurebayashi, M D Tronko, S Yamashita.   

Abstract

Understanding the detailed mechanisms of a chemotherapeutic agent action on cancer cells is essential for planning the clinical applications because drug effects are often tissue and cell type specific. This study set out to elucidate the molecular pathways of Taxol effects in human anaplastic thyroid cancer cells using as an experimental model four cell lines, ARO, KTC-2, KTC-3 (anaplastic thyroid cancer), and FRO (undifferentiated follicular cancer), and primary thyrocytes. All cell lines were sensitive to Taxol, although to different extent. In primary thyrocytes the drug displayed substantially lower cytotoxicity. In thyroid cancer cells, Taxol-induced changes characteristic to apoptosis such as poly (ADP-ribose) polymerase and procaspase cleavage and alteration of membrane asymmetry only within a narrow concentration range, from 6 to 50 nm. At higher concentration, other form(s) of cell death perhaps associated with mitochondrial collapse was observed. Low doses of Taxol enhanced Bcl2 phosphorylation and led to its degradation observed on the background of a sustained or increasing Bax level and accumulation of survivin and X-chromosome-linked inhibitor of apoptosis. c-jun-NH(2) terminal kinase activation was essential for the apoptosis in anaplastic thyroid cancer cells, whereas Raf/MAPK kinase/ERK and phosphatidylinositol-3-OH kinase/Akt were likely to comprise main survival mechanisms. Our results suggest an importance of cautious interpreting of biological effects of Taxol in laboratory studies and for determining optimal doses of Taxol to achieve the desired therapeutic effect in anaplastic thyroid cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044368     DOI: 10.1210/en.2004-0127

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Authors:  Laura A Marlow; Stephen D Rohl; James L Miller; Jeffery A Knauf; James A Fagin; Mabel Ryder; Dragana Milosevic; Brian C Netzel; Stefan K Grebe; Honey V Reddi; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

2.  Lead optimization of dual tubulin and Hsp27 inhibitors.

Authors:  Bo Zhong; Rati Lama; Daniel G Kulman; Bibo Li; Bin Su
Journal:  Eur J Med Chem       Date:  2014-04-13       Impact factor: 6.514

3.  Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells.

Authors:  EunSook Kim; Michiko Matsuse; Vladimir Saenko; Keiji Suzuki; Akira Ohtsuru; Norisato Mitsutake; Shunichi Yamashita
Journal:  Thyroid       Date:  2012-05-31       Impact factor: 6.568

Review 4.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

5.  Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry.

Authors:  Julio R Gaspar; Jun Qu; Ninfa L Straubinger; Robert M Straubinger
Journal:  Analyst       Date:  2008-10-03       Impact factor: 4.616

6.  Microtubule-interacting drugs induce moderate and reversible damage to human bone marrow mesenchymal stem cells.

Authors:  H Polioudaki; M-C Kastrinaki; H A Papadaki; P A Theodoropoulos
Journal:  Cell Prolif       Date:  2009-05-22       Impact factor: 6.831

7.  Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.

Authors:  Shu-Fu Lin; Sizhi Paul Gao; Daniel L Price; Sen Li; Ting-Chao Chou; Paramjeet Singh; Yu-Yao Huang; Yuman Fong; Richard J Wong
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

8.  The effect of the combined action of roscovitine and Paclitaxel on the apoptotic and cell cycle regulatory mechanisms in colon and anaplastic thyroid cancer cells.

Authors:  V V Pushkarev; O I Kovzun; V M Pushkarev; M D Tronko
Journal:  ISRN Biochem       Date:  2012-08-30

9.  Cordycepin enhances cisplatin apoptotic effect through caspase/MAPK pathways in human head and neck tumor cells.

Authors:  Ying-Hui Chen; Jo-Yu Wang; Bo-Syong Pan; Yi-Fen Mu; Meng-Shao Lai; Edmund Cheung So; Thian-Sze Wong; Bu-Miin Huang
Journal:  Onco Targets Ther       Date:  2013-07-25       Impact factor: 4.147

Review 10.  The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer.

Authors:  Nerina Denaro; Cristiana Lo Nigro; Elvio G Russi; Marco C Merlano
Journal:  Onco Targets Ther       Date:  2013-09-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.